HemaQuest Lands Series B Extension Funding Worth $13M

HemaQuest Pharmaceuticals, Inc. recently gained $13 million worth of extension funding for their Series B round. This additional financing was participated in by Aberdare Ventures, Forward Ventures, and Lilly Ventures. Other existing investors like De Novo Ventures and Latterell Venture Partners also took part in this extension.

The company’s Chief Financial Officer, Tamara Seymour, recently shared a bit more about the company in this recent e-interview with Lead411:

Read More